Know Cancer

or
forgot password

Melanoma Lifestyle Study


N/A
N/A
N/A
Open (Enrolling)
Both
Melanoma (Skin)

Thank you

Trial Information

Melanoma Lifestyle Study


OBJECTIVES:

- To examine the findings of the pilot study, that vitamin D supplementation in
combination with vitamin D receptor (VDR) polymorphisms protects from late relapse
(after 3 years) in patients who have had melanoma.

- To investigate the effects of vitamin D supplement dosage in reducing the risk of late
relapse.

- To examine if vitamin D supplementation in combination with particular VDR
polymorphisms protects from early relapse (before 3 years).

- To examine if serum levels of vitamin D correlate with risk of relapse in groups of
patients with different VDR polymorphisms.

- To examine the effect of vitamin supplementation and VDR status on time to relapse and
survival in these patients.

- To examine other factors that may affect risk of relapse by assembling a tissue
(genomic DNA and serum) resource.

- To investigate the effect of exposure to incidental drugs, such as statins, on risk of
relapse in these patients.

OUTLINE: Patients are stratified according to disease relapse in the past 5 years (yes vs
no).

Patients are asked to complete a food frequency questionnaire focusing on vitamin D and the
following area: supplementation of diet with vitamins/fish oil and duration of use; sun
exposure and sunscreen-use per decade prior to and after diagnosis. Patients are also asked
to provide a blood sample for serum and DNA analysis. Consenting patients are also tagged
with the Office of National Statistics to allow passive follow up.

Stored tissue from the patient's primary melanoma may be used to corroborate research
findings using immunohistochemistry or studies of gene expression, polymorphism, or
mutation.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosed with melanoma

- Must meet either of the following conditions:

- Resected stage IB, II, or IIIA disease that has relapsed as either stage III or
IV disease (cases)

- First loco regional and/or visceral relapse (with/without sentinel node
biopsy)

- No more than 3 months since first relapse

- Resected stage IB, II, or IIIA disease that has not relapsed for ≥ 5 years
(controls)

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Odds ratio (OR) for vitamin D supplementation in relapse

Safety Issue:

No

Principal Investigator

Julia Newton Bishop, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Leeds Cancer Centre at St. James's University Hospital

Authority:

Unspecified

Study ID:

CDR0000587987

NCT ID:

NCT00672321

Start Date:

December 2007

Completion Date:

Related Keywords:

  • Melanoma (Skin)
  • recurrent melanoma
  • stage IB melanoma
  • stage II melanoma
  • stage IIIA melanoma
  • Melanoma

Name

Location